Compare OPXS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPXS | BOLD |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | 72 | N/A |
| Industry | Electronic Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.9M | 60.8M |
| IPO Year | 2009 | 2024 |
| Metric | OPXS | BOLD |
|---|---|---|
| Price | $9.60 | $2.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.5K | ★ 199.4K |
| Earning Date | 08-11-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.55 | 32.47 |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $24,530,000.00 | N/A |
| Revenue This Year | $3.54 | N/A |
| Revenue Next Year | $10.05 | N/A |
| P/E Ratio | $23.66 | ★ N/A |
| Revenue Growth | ★ 17.63 | N/A |
| 52 Week Low | $9.04 | $0.96 |
| 52 Week High | $17.62 | $3.16 |
| Indicator | OPXS | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 34.82 | 37.70 |
| Support Level | $9.04 | $1.40 |
| Resistance Level | $10.85 | $2.71 |
| Average True Range (ATR) | 0.32 | 0.16 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 11.05 | 25.58 |
Optex Systems Holdings Inc manufactures optical sighting systems and assemblies for the U.S. Department of Defense, foreign military applications, and commercial markets. Its products are installed on a variety of United States military land vehicles, such as the Abrams and Bradley fighting vehicles, light armored and security vehicles, and have been selected for installation on the Stryker family of vehicles. The company's operating segment includes Optex Systems Richardson, Applied Optics Center Dallas, and others. It generates maximum revenue from the Optex Systems Richardson segment. Some of its products include M17 Day/Thermal Periscope; DDAN / M36 Sights; Laser Protected Periscopes; Muzzle Reference Sensor, and others.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.